← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Inhibrx, Inc.
La Jolla, CA
$1,821,179
Total funding
4
Grants
Funding over time
peak $1.4M · FY2017–21$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,448,556 · 2
DOD$372,623 · 2
By mechanism
R44$1,224,154 · 1
—$372,623 · 2
R43$224,402 · 1
Investigators at Inhibrx, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$936,939
R44 · FY2017 · AI
DEVELOPMENT OF MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF ACINETOBACTER BAUMANNI$252,486
· FY2018 · Defense Health Agency
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$223,854
R44 · FY2017 · AI
DEVELOPMENT OF SINGLE DOMAIN ANTIBODY (SDAB) BASED THERAPEUTICS TARGETING SARS-COV-2 SPIKE PROTEIN FOR THE TREATMENT OF COVID-19$120,137
· FY2021 · Defense Health Agency
Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus âaureus (MRSA) infection$116,006
R43 · FY2017 · AI
Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus âaureus (MRSA) infection$108,396
R43 · FY2017 · AI
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$63,361
R44 · FY2017 · AI